Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 8/20 | 0.31 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30227824 | 0.86 | CYP17A1 (0.31) | CYP17A1CYP3A4 | |
| SCHEMBL23988247 | 0.86 | CYP17A1 (0.31) | CYP17A1CYP3A4 | |
| SCHEMBL21990701 | 0.83 | PIK3CD (0.34) | CYP17A1CYP3A4 | |
| SCHEMBL30227741 | 0.83 | PIK3CD (0.34) | CYP17A1CYP3A4 | |
| SCHEMBL21990455 | 0.79 | MAP4K1 (0.36) | MAP4K1CYP17A1CYP3A4 | |
| SCHEMBL30227903 | 0.79 | MAP4K1 (0.36) | MAP4K1CYP17A1CYP3A4 | |
| SCHEMBL21990556 | 0.77 | MAP4K1 (0.32) | MAP4K1CYP17A1CYP3A4 | |
| SCHEMBL30227910 | 0.77 | MAP4K1 (0.32) | MAP4K1CYP17A1CYP3A4 | |
| SCHEMBL21964196 | 0.77 | MAP4K1 (0.33) | MAP4K1 | |
| SCHEMBL24758584 | 0.76 | RPS6KA2 (0.43) | MAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11684616-B2 | Azalactam compounds as HPK1 inhibitors | PFIZER INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11684616-B2 | Azalactam compounds as HPK1 inhibitors | PFIZER INC. (US) | 2023-06-27 | — | — | US | disclosed |
| WO-2023057882-A1 | COMBINATIONS OF AZALACTAM COMPOUNDS WITH A PD-1 AXIS BINDING ANTAGONIST FOR THE TREATMENT OF CANCER | PFIZER INC. (US) | 2023-04-13 | — | — | WO | disclosed |
| EP-4143186-A1 | AZALACTAM COMPOUNDS AS HPK1 INHIBITORS | Pfizer Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20220401424-A1 | Azalactam Compounds as HPK1 Inhibitors | PFIZER INC. (US) | 2022-12-22 | — | — | US | disclosed |
| WO-2021220185-A1 | AZALACTAM COMPOUNDS AS HPK1 INHIBITORS | PFIZER INC. (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220401424-A1 | Azalactam Compounds as HPK1 Inhibitors | CDKN1A, HIPK1, CMPK1 | MAP4K1 108/4885CYP17A1 2762/4885CYP3A4 3058/4885 |
| US-11684616-B2 | Azalactam compounds as HPK1 inhibitors | CDKN1A, HIPK1, CMPK1 | MAP4K1 108/4885CYP17A1 2762/4885CYP3A4 3058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.